Intercept’s NASH drug fails late-stage trial, shares tumbleBusiness, Clinical Trials, R&D, TherapeuticsIntercept Pharmaceuticals Inc. said on Friday its treatment for patients with advanced liver scarring due to non-alcoholic steatohepatitis (NASH) failed to meet the main goal of a late-stage study, sending its shares down as much as 21%. Read more September 30, 2022/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2022/07/InterceptPharma-2022.jpg 600 992 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2022-09-30 11:06:432022-09-30 11:22:32Intercept’s NASH drug fails late-stage trial, shares tumble
